-
1
-
-
0020521843
-
Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors
-
Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-1841.
-
(1983)
J Clin Invest
, vol.71
, pp. 1836-1841
-
-
Hedner, U.1
Kisiel, W.2
-
2
-
-
0023763216
-
Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy
-
Hedner U, Glazer S, Pingel K et al. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet 1988; 2: 1193.
-
(1988)
Lancet
, vol.2
, pp. 1193
-
-
Hedner, U.1
Glazer, S.2
Pingel, K.3
-
3
-
-
34249821653
-
Prevention and treatment of major blood loss
-
Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356: 2301-2311.
-
(2007)
N Engl J Med
, vol.356
, pp. 2301-2311
-
-
Mannucci, P.M.1
Levi, M.2
-
4
-
-
33646487022
-
Mechanism of action of factor VIIa in the treatment of coagulopathies
-
Hedner U. Mechanism of action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 2006; 32 Suppl 1: 77-85
-
(2006)
Semin Thromb Hemost
, vol.32
, Issue.SUPPL. 1
, pp. 77-85
-
-
Hedner, U.1
-
5
-
-
0027302704
-
The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor
-
Ten Cate H, Bauer KA, Levi M et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-1212.
-
(1993)
J Clin Invest
, vol.92
, pp. 1207-1212
-
-
Ten Cate, H.1
Bauer, K.A.2
Levi, M.3
-
6
-
-
4444277942
-
Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux
-
Lisman T, Bijsterveld NR, Adelmeijer J et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-2373.
-
(2003)
J Thromb Haemost
, vol.1
, pp. 2368-2373
-
-
Lisman, T.1
Bijsterveld, N.R.2
Adelmeijer, J.3
-
7
-
-
0033758876
-
Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors
-
Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000; 26: 425-432.
-
(2000)
Semin Thromb Hemost
, vol.26
, pp. 425-432
-
-
Ingerslev, J.1
-
8
-
-
0032725116
-
Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa
-
Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999; 82: 531-539.
-
(1999)
Thromb Haemost
, vol.82
, pp. 531-539
-
-
Hedner, U.1
-
9
-
-
0031788228
-
Recombinant activated factor VII as a universal haemostatic agent
-
Hedner U. Recombinant activated factor VII as a universal haemostatic agent. Blood Coagul Fibrinolysis 1998; 9: S147-152.
-
(1998)
Blood Coagul Fibrinolysis
, vol.9
-
-
Hedner, U.1
-
10
-
-
0037452134
-
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: A double-blind placebo-controlled randomised trial
-
Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-205.
-
(2003)
Lancet
, vol.361
, pp. 201-205
-
-
Friederich, P.W.1
Henny, C.P.2
Messelink, E.J.3
-
11
-
-
18144393811
-
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: A double-blind, randomized, placebo-controlled trial
-
Raobaikady R, Redman J, Ball JA et al. Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial. Br J Anaesth 2005; 94: 586-591.
-
(2005)
Br J Anaesth
, vol.94
, pp. 586-591
-
-
Raobaikady, R.1
Redman, J.2
Ball, J.A.3
-
12
-
-
27744513120
-
Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: Randomized double-blind placebo-controlled pilot study
-
Diprose P, Herbertson MJ, O'Shaughnessy D et al. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth 2005; 95: 596-602.
-
(2005)
Br J Anaesth
, vol.95
, pp. 596-602
-
-
Diprose, P.1
Herbertson, M.J.2
O'Shaughnessy, D.3
-
13
-
-
0035865124
-
Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: A pilot study
-
Hendriks HG, Meijer K, de Wolf JT et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 2001; 71: 402-405.
-
(2001)
Transplantation
, vol.71
, pp. 402-405
-
-
Hendriks, H.G.1
Meijer, K.2
de Wolf, J.T.3
-
14
-
-
23744438763
-
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease
-
Planinsic RM, van der MJ, Testa G et al. Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease. Liver Transpl 2005; 11: 895-900.
-
(2005)
Liver Transpl
, vol.11
, pp. 895-900
-
-
Planinsic1
RM, V.D.M.2
Testa, G.3
-
15
-
-
23744440522
-
Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation
-
Lodge JP, Jonas S, Jones RM et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-979.
-
(2005)
Liver Transpl
, vol.11
, pp. 973-979
-
-
Lodge, J.P.1
Jonas, S.2
Jones, R.M.3
-
16
-
-
17044369884
-
Recombinant factor VIIa in partial hepatectomy: A randomized placebo-controlled, double-blind clinical trial
-
Lodge P, Jonas S, Jaeck D et al. Recombinant factor VIIa in partial hepatectomy: A randomized placebo-controlled, double-blind clinical trial. J Hepatol 2003; 36: 177.
-
(2003)
J Hepatol
, vol.36
, pp. 177
-
-
Lodge, P.1
Jonas, S.2
Jaeck, D.3
-
17
-
-
0033610715
-
Treatment of traumatic bleeding with recombinant factor VIIa
-
Kenet G, Waiden R, Eldad A et al. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879.
-
(1999)
Lancet
, vol.354
, pp. 1879
-
-
Kenet, G.1
Waiden, R.2
Eldad, A.3
-
18
-
-
0034778413
-
Recombinant activated factor VII for adjunctive hemorrhage control in trauma
-
Martinowitz U, Kenet G, Segal E et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001; 51: 431-438.
-
(2001)
J Trauma
, vol.51
, pp. 431-438
-
-
Martinowitz, U.1
Kenet, G.2
Segal, E.3
-
19
-
-
0036686745
-
The effect of recombinant factor VIIa on coagulopathy pigs with grade V liver injuries
-
Schreiber MA, Holcomb JB, Hedner U et al. The effect of recombinant factor VIIa on coagulopathy pigs with grade V liver injuries. J Trauma 2002; 53: 252-257.
-
(2002)
J Trauma
, vol.53
, pp. 252-257
-
-
Schreiber, M.A.1
Holcomb, J.B.2
Hedner, U.3
-
20
-
-
0038327506
-
The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries
-
Schreiber MA, Holcomb JB, Hedner U et al. The effect of recombinant factor VIIa on noncoagulopathic pigs with grade V liver injuries. J Am Coll Surg 2003; 196: 691-697.
-
(2003)
J Am Coll Surg
, vol.196
, pp. 691-697
-
-
Schreiber, M.A.1
Holcomb, J.B.2
Hedner, U.3
-
21
-
-
24644491444
-
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials
-
Boffard KD, Riou B, Warren B et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15.
-
(2005)
J Trauma
, vol.59
, pp. 8-15
-
-
Boffard, K.D.1
Riou, B.2
Warren, B.3
-
22
-
-
41149168687
-
Efficacy and safety of recombinant activated factor vii in major surgical procedures: Systematic review and meta-analysis of randomized clinical trials
-
Ranucci M, Isgro G, Soro G et al. Efficacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 2008; 143: 296-304.
-
(2008)
Arch Surg
, vol.143
, pp. 296-304
-
-
Ranucci, M.1
Isgro, G.2
Soro, G.3
-
23
-
-
40549089223
-
Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: A review and meta-analysis of published data
-
Von Heymann C, Jonas S, Spies C et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care 2008; 12: R14.
-
(2008)
Crit Care
, vol.12
-
-
Von Heymann, C.1
Jonas, S.2
Spies, C.3
-
24
-
-
0034019122
-
Recombinant Factor VIIa is a panhemostatic agent?
-
Aledort LM. Recombinant Factor VIIa is a panhemostatic agent? Thromb Haemost 2000; 83: 637-638.
-
(2000)
Thromb Haemost
, vol.83
, pp. 637-638
-
-
Aledort, L.M.1
-
25
-
-
34548214668
-
Disseminated intravascular coagulation
-
Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35: 2191-2195.
-
(2007)
Crit Care Med
, vol.35
, pp. 2191-2195
-
-
Levi, M.1
-
26
-
-
0031756987
-
Clinical experience with activated factor VII: Focus on safety aspects
-
Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagul Fibrinolysis 1998; 9: S115-118.
-
(1998)
Blood Coagul Fibrinolysis
, vol.9
-
-
Roberts, H.R.1
-
27
-
-
0032730115
-
Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor
-
Peerlinck K, Vermylen J. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor. Thromb Haemost 1999; 82: 1775-1776.
-
(1999)
Thromb Haemost
, vol.82
, pp. 1775-1776
-
-
Peerlinck, K.1
Vermylen, J.2
-
28
-
-
0033824021
-
rFVIIa - its thrombogenicity
-
Aledort LM. rFVIIa - its thrombogenicity. Thromb Haemost 2000; 84: 522-523.
-
(2000)
Thromb Haemost
, vol.84
, pp. 522-523
-
-
Aledort, L.M.1
-
29
-
-
13244262642
-
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
-
Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004; 2: 1700-1708.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1700-1708
-
-
Aledort, L.M.1
-
30
-
-
17044405174
-
Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: A systematic review
-
Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for the treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890.
-
(2005)
Crit Care Med
, vol.33
, pp. 883-890
-
-
Levi, M.1
Peters, M.2
Buller, H.R.3
-
31
-
-
13844315293
-
Recombinant activated factor VII for acute intracerebral hemorrhage
-
Mayer SA, Brun NC, Begtrup K et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352 :777-785.
-
(2005)
N Engl J Med
, vol.352
, pp. 777-785
-
-
Mayer, S.A.1
Brun, N.C.2
Begtrup, K.3
-
32
-
-
30944461398
-
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa
-
O'Connell KA, Wood JJ, Wise RP et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-298.
-
(2006)
JAMA
, vol.295
, pp. 293-298
-
-
O'Connell, K.A.1
Wood, J.J.2
Wise, R.P.3
|